The Need for Individualized Risk Assessment in Cardiovascular Disease

J Pers Med. 2022 Jul 14;12(7):1140. doi: 10.3390/jpm12071140.

Abstract

Cardiovascular disease remains the leading cause of death in the era of modern medicine despite major advancements in this field. Current available clinical surrogate markers and blood tests do not adequately predict individual risk of cardiovascular disease. A more precise and sophisticated tool that can reliably predict the thrombosis and bleeding risks at an individual level is required in order for clinicians to confidently recommend early interventions with a favorable risk-benefit profile. Critical to the development of this tool is the assessment and understanding of Virchow's triad and its complex interactions between hypercoagulability, endothelial dysfunction and vessel flow, a fundamental concept to the development of thrombosis. This review explores the pathophysiology of cardiovascular disease stemming from the triad of factors and how individualized risk assessment can be improved through the multimodal use of tools such as global coagulation assays, endothelial biomarkers and vessel flow assessment.

Keywords: Virchow’s triad; cardiovascular disease; endothelial markers; global coagulation assays; risk assessment.

Publication types

  • Review

Grants and funding

This research received no external funding.